Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$1.44 - $3.44 $329 - $787
-229 Reduced 99.13%
2 $0
Q3 2022

Nov 10, 2022

BUY
$3.35 - $5.55 $636 - $1,054
190 Added 463.41%
231 $1,000
Q2 2022

Aug 12, 2022

SELL
$3.12 - $7.52 $38,641 - $93,135
-12,385 Reduced 99.67%
41 $0
Q1 2022

May 16, 2022

SELL
$6.26 - $14.42 $8,163 - $18,803
-1,304 Reduced 9.5%
12,426 $89,000
Q4 2021

Feb 14, 2022

SELL
$11.35 - $21.18 $267,054 - $498,344
-23,529 Reduced 63.15%
13,730 $187,000
Q3 2021

Nov 12, 2021

BUY
$18.17 - $24.7 $520,625 - $707,729
28,653 Added 332.94%
37,259 $780,000
Q2 2021

Aug 16, 2021

BUY
$20.08 - $29.02 $172,808 - $249,746
8,606 New
8,606 $206,000

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $51.1M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.